Evidence map›Paper›PMID 28589550›Full record

ArticleInternational journal of urology : official journal of the Japanese Urological Association2017

Characterization of a "low-risk" cohort of grade group 2 prostate cancer patients: Results from the Shared Equal Access Regional Cancer Hospital database.

Kathleen F McGinley, Xizi Sun, Lauren E Howard, William J Aronson, Martha K Terris, Christopher J Kane, Christopher L Amling, Matthew R Cooperberg, Stephen J Freedland

Abstract read
In one paragraph

Article in International journal of urology : official journal of the Japanese Urological Association, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kathleen F McGinleyDivision of Urology, Department of Surgery, Duke University, Durham, North Carolina, USA.
Xizi SunDivision of Urology, Veterans Affairs Medical Center, Durham, North Carolina, USA.
Lauren E HowardDivision of Urology, Veterans Affairs Medical Center, Durham, North Carolina, USA.
William J AronsonUrology Section, Department of Surgery, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California, USA.
Martha K TerrisSection of Urology, Veterans Affairs Medical Center, Augusta, Georgia, USA.
Christopher J KaneUrology Department, University of California San Diego Health System, San Diego, California, USA.
Christopher L AmlingDepartment of Urology, Oregon Health Sciences University, Portland, Oregon, USA.
Matthew R CooperbergDepartment of Urology, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA.
Stephen J FreedlandDivision of Urology, Veterans Affairs Medical Center, Durham, North Carolina, USA.

Funding

UCLA SPORE IN PROSTATE CANCERP50CA092131 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI FREEMAN, MICHAEL R · 2002 to 2023
$42.6M
Midcareer Investigator AwardK24CA160653 · NCI · DUKE UNIVERSITY · PI FREEDLAND, STEPHEN JAY · 2012 to 2016
$877k
NCI NIH HHS K24 CA160653NCI NIH HHS P50 CA092131
6 · The paper itself

Abstract

objectivesTo examine if there is a subset of men with grade group 2 prostate cancer who could be potential candidates for active surveillance.

methodsWe used the Shared Equal Access Regional Cancer Hospital database to identify 776 men undergoing radical prostatectomy from 2006 to 2015 with >8 biopsy cores obtained and complete information. We compared men who fulfilled low-risk disease criteria (clinical stage T1c/T2a; grade group 1; prostate-specific antigen ≤10 ng/mL) with the exception of grade group 2 versus men who met all three low-risk criteria. Logistic regression was used to test the association between grade group and radical prostatectomy pathological features. Biochemical recurrence was examined using Cox models. To examine whether there was a subset of men with low-volume grade group 2 with comparable outcomes to low-risk men, we repeated all analyses limiting the percentage of positive cores in the grade group 2 group to ≤33%, and positive cores to ≤4, ≤3 or ≤2.

resultsGrade group 2 low-risk men had increased risk of pathological grade group 3 or higher (P < 0.001), extraprostatic extension (P < 0.001), seminal vesicle invasion (P < 0.001) and higher risk of biochemical recurrence (hazard ratio = 1.76, P = 0.006). Using increasingly strict definitions of low-volume disease, at ≤2 positive cores there was no difference in adverse pathology between groups (all P > 0.2), except higher pathological grade group (P = 0.006). Biochemical recurrence was similar in men in grade group 1 and grade group 2 (hazard ratio = 1.24; P = 0.529).

conclusionsAmong men with prostate-specific antigen ≤10 ng/mL and clinical stage T1c/T2a, those in grade group 2 with ≤2 total positive cores have similar rates of adverse pathology and biochemical recurrence as men with grade group 1.

Indexed as

Watchful WaitingAgedBiopsy, NeedleCancer Care FacilitiesDatabases, FactualHumansMaleMiddle AgedNeoplasm GradingNeoplasm Recurrence, LocalNeoplasm StagingPatient SelectionProstateProstatectomyProstate-Specific AntigenProstatic NeoplasmsProstate-Specific Antigenbiopsyneoplasm gradingneoplasm recurrenceprostate cancerprostatectomy

Identifiers

PMID28589550
PMCPMC6986736

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.